IJR News — today's news from every side
block
verse
w
o
rdys
billionaire
.ai
your
list
Whiteboard
App
quizie
un
school
New Journal
Loading
Ask Genius
Apps
News
Home
Politics
World
Sports
Markets
Business
Entertainment
Music
Health
Tech
Science
Good News
Encouragement
Video
Meme Wars
Brands
Yourlist
Quizie
F
FaithTap
B
Blessed
All brands
Ask Genius
Apps
Trending
📊 Approval movers
Gordon Liu
100%
Trump to Rename Department of Defense, Reverting to Former Name: Report
x/donald-john-trump
— Sep 5, 2025
President Donald Trump is expected to sign an executive order Friday that will change the Department of Defense to become the Department of War, according to a report. The “new” name will actually revert the department…
Share
It’s Illegal to Tell Your Gender-Confused Son He’s a Boy But You Can Tell Him He’s a Girl: Canada
Reporting
— Jan 19, 2022
As time goes on, the stories of detransitioners — individuals who once identified as transgender, but then reverted back to identifying with their biological sex — become more and more prevalent. Often, these cases…
Share
Trump Pressures Commanders to Revert Name in Stadium Talks
x/donald-john-trump
— Jul 21, 2025
President Donald Trump’s latest comments are already shaking up a stadium deal that was supposed to be routine. On Sunday, in a series of posts on Truth Social, Trump said he might pressure the Washington Commanders to…
Share
Trump Says DC Won’t Be Reverting Back To A Sanctuary City Under His Watch
x/donald-john-trump
— Sep 15, 2025
President Donald Trump declared Monday that he “won’t allow” the nation’s capital to fall back into being a sanctuary city that refuses to cooperate with federal immigration authorities. Trump is prepared to call a…
Share
IJR
EXCLUSIVE: Trump’s EPA Wants More Plastic Turned Into New Products, And The Paper Lobby Is Fighting It
Simon August · 4 min · 14h
Novartis Phase 3 Pelacarsen Trial Misses Cardiovascular Endpoint
x/novartis
— Sep 5, 2026
Novartis reported that the Phase III Lp(a)HORIZON trial did not meet its primary endpoint, showing that lowering Lp(a) with pelacarsen reduced levels but did not significantly reduce cardiovascular events in approximately 8,000 patients on guideline-directed therapy; the company said full data will be presented at a future medical congress. Meanwhile, Royalty Pharma outlined its financial stance on the pelacarsen investment, noting the trial’s failure won’t derail its recovery of invested funds and that royalties on Spinraza remain a key part of its portfolio as it pursues its 2030 receipts target, with Ionis royalties potentially reverting after a defined cap. The developments reflect a broader scientific and market reevaluation of Lp(a)-targeted therapies and their commercial prospects.
+3
3
Share
Jared Kim
Wonder how many other Lp(a) drugs in the pipeline just got a lot riskier to fund after this readout.
Yourlist
Ranking
Most Influential Women in World History
From ancient queens who ruled empires to modern activists who changed laws, these women left indelible marks on politics, science, and culture. Vote for who you think shaped history most profoundly.
1379 votes · 26 candidates
GOP Senator Rips Biden Over Rittenhouse Comment, Says Dems Continue to Revert to Name-Calling
Reporting
— Nov 11, 2021
Arkansas Republican Sen. Tom Cotton ripped President Joe Biden’s remark that labeled Kyle Rittenhouse a “white supremacist” in a Twitter post last year without considering the evidence. Cotton shared the comments during…
Share
